首页> 外文期刊>Immunopharmacology and immunotoxicology >Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
【24h】

Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.

机译:复发-缓解型多发性硬化症患者在干扰素-β1a治疗下的白细胞介素10和白细胞介素12调节:反应者和非反应者的差异。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10/IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10/IL-12 ratio as a serum marker predictive of favorable clinical course.
机译:我们检查了干扰素(IFN)β-1a对27例复发缓解型多发性硬化症(RRMS)患者白细胞介素(IL)-12p70和IL-10分泌的影响,分为反应者和非反应者。在应答者中,IFNbeta-1a不会改变IL-12p70的浓度,但会导致IL-10的产生显着增加。此外,在治疗的头六个月期间显示出高的IL-10 / IL-12比。在无反应者中,细胞因子谱没有明显改变。我们建议,IFNβ-1a在RRMS患者中的作用可以通过其对细胞因子模式的修饰作用来解释。此外,我们提出IL-10 / IL-12比率作为预测良好临床过程的血清标志物的可能作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号